Thermo Fisher Scientific (TMO) is reportedly closing in on a major acquisition that could strengthen its presence in clinical research technology. According to The Financial Times, the life sciences company is nearing a roughly $10 billion all-cash deal to acquire Clario, a company that provides digital data and software solutions to optimize clinical trials and improve patient outcomes.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sources familiar with the situation say that discussions have progressed significantly, and an announcement could come as soon as Wednesday if no unexpected issues arise. They also noted that the final terms may still change, and there is a chance the deal may not be completed.
What the Deal Could Mean for Both Sides
Thermo Fisher provides advanced tools, technologies, and services for scientific research and healthcare. If finalized, the deal would further expand Thermo Fisher’s capabilities in supporting pharmaceutical and biotech customers as demand for advanced clinical trial tools continues to rise. With this move, Thermo Fisher would expand into a key area of drug development, since Clario’s software is widely used to collect and manage clinical trial data.
Additionally, the deal would be one of the largest private equity exits this year for Clario. The company was formed in 2021 through the merger of ERT and Bioclinica and is mainly owned by Nordic Capital, a private equity firm based in Stockholm. Clario’s other investors include Astorg Partners, Novo Holdings, and Cinven.
Notably, Clario has supported more than 26,000 trials and contributed to around 800 drug approvals, and the company brings in roughly $400 million in adjusted annual earnings.
Is Thermo Fisher a Good Stock to Buy?
On TipRanks, TMO stock has a consensus Strong Buy rating among 19 Wall Street analysts. That rating is based on 16 Buys and three Holds assigned in the last three months. The average Thermo Fisher stock price target of $615.76 implies a 10.42% upside from current levels.
